Yun Zhong
Stock Analyst at Wedbush
(1.19)
# 3,551
Out of 4,876 analysts
32
Total ratings
39.29%
Success rate
-13.68%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yun Zhong
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WVE Wave Life Sciences | Reiterates: Outperform | $18 | $6.67 | +169.87% | 1 | Jun 23, 2025 | |
| KROS Keros Therapeutics | Reiterates: Neutral | $15 | $13.49 | +11.19% | 2 | May 30, 2025 | |
| CAMP Camp4 Therapeutics | Initiates: Outperform | $8 | $1.52 | +426.32% | 1 | May 27, 2025 | |
| RCKT Rocket Pharmaceuticals | Reiterates: Outperform | $32 | $2.53 | +1,164.82% | 2 | May 16, 2025 | |
| ASND Ascendis Pharma | Maintains: Outperform | $181 → $212 | $172.14 | +23.16% | 1 | May 2, 2025 | |
| PTGX Protagonist Therapeutics | Reiterates: Outperform | $70 | $55.69 | +25.70% | 2 | Mar 28, 2025 | |
| VYGR Voyager Therapeutics | Reiterates: Outperform | n/a | $2.96 | - | 1 | Mar 12, 2025 | |
| PASG Passage Bio | Assumes: Outperform | $4 | $0.33 | +1,108.09% | 2 | Nov 29, 2024 | |
| MLTX MoonLake Immunotherapeutics | Assumes: Outperform | $92 → $73 | $47.52 | +53.62% | 1 | Nov 5, 2024 | |
| RZLT Rezolute | Initiates: Outperform | $12 | $4.35 | +175.86% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $28 | $9.48 | +195.36% | 2 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.38 | - | 2 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $16 | $5.93 | +169.81% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $160 | $17.11 | +835.13% | 11 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $46 | $13.86 | +231.89% | 1 | Jun 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $2.66 | +275.94% | 1 | May 5, 2021 |
Wave Life Sciences
Jun 23, 2025
Reiterates: Outperform
Price Target: $18
Current: $6.67
Upside: +169.87%
Keros Therapeutics
May 30, 2025
Reiterates: Neutral
Price Target: $15
Current: $13.49
Upside: +11.19%
Camp4 Therapeutics
May 27, 2025
Initiates: Outperform
Price Target: $8
Current: $1.52
Upside: +426.32%
Rocket Pharmaceuticals
May 16, 2025
Reiterates: Outperform
Price Target: $32
Current: $2.53
Upside: +1,164.82%
Ascendis Pharma
May 2, 2025
Maintains: Outperform
Price Target: $181 → $212
Current: $172.14
Upside: +23.16%
Protagonist Therapeutics
Mar 28, 2025
Reiterates: Outperform
Price Target: $70
Current: $55.69
Upside: +25.70%
Voyager Therapeutics
Mar 12, 2025
Reiterates: Outperform
Price Target: n/a
Current: $2.96
Upside: -
Passage Bio
Nov 29, 2024
Assumes: Outperform
Price Target: $4
Current: $0.33
Upside: +1,108.09%
MoonLake Immunotherapeutics
Nov 5, 2024
Assumes: Outperform
Price Target: $92 → $73
Current: $47.52
Upside: +53.62%
Rezolute
Nov 5, 2024
Initiates: Outperform
Price Target: $12
Current: $4.35
Upside: +175.86%
Feb 9, 2023
Maintains: Buy
Price Target: $35 → $28
Current: $9.48
Upside: +195.36%
Feb 2, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.38
Upside: -
Jan 18, 2023
Maintains: Buy
Price Target: $14 → $16
Current: $5.93
Upside: +169.81%
Dec 22, 2022
Maintains: Buy
Price Target: $125 → $160
Current: $17.11
Upside: +835.13%
Jun 15, 2021
Initiates: Buy
Price Target: $46
Current: $13.86
Upside: +231.89%
May 5, 2021
Initiates: Buy
Price Target: $10
Current: $2.66
Upside: +275.94%